Photocure Asa (PHO.OL) traded up 1.22 % during a 24 hours period ending at 10:06 PM Central Europe on Tuesday 27th. One Photocure Asa stock can currently be bought for about NOK 50 on popular exchanges. Current supply of Photocure Asa stocks is 26.8 mn. Photocure Asa has a current market capitalization of NOK 1.3 bn and approximately NOK 1.2 mn worth of Photocure Asa was traded on exchanges in the last 24 hours. Since last month end, Photocure Asa has traded 1.22 % up. Simple moving average of last 200 days is at NOK 60.2. The highest price of past 52 weeks was recorded at NOK 79.8 on 01/15/2026. 52 weeks low was at NOK 46.25 on 08/04/2026.

Summary of the latest news for Photocure Asa

ABG Sundal Collier has revised its target price for Photocure ASA downward, setting a new forecast at 70 Norwegian kroner while maintaining a positive stance on the stock. The broker reiterated its recommendation to buy the shares, indicating a continued confidence in the company’s prospects despite the adjustment in expected valuation.

Here is how related stocks have performed in the past 24 hours:

  • Eidesvik Offshore Asa (EIOF.OL) traded down -3.09 % and now trades at NOK 17.15. Current market capitalisation for Eidesvik Offshore Asa is NOK 1.3 bn. Current price/earnings ratio for Eidesvik Offshore Asa is 23.68.

  • Tekna Asa (TEKNA.OL) traded up 2 % and now trades at NOK 6. Current market capitalisation for Tekna Asa is NOK 1.4 bn.

  • Magnora Asa (MGN.OL) traded down -0.63 % and now trades at NOK 19.36. Magnora Asa has a market capitalisation of NOK 1.4 bn.

  • Fjord Defence Asa (DFENS.OL) traded up 0.83 % and now trades at NOK 12.55. Fjord Defence Asa has a market capitalisation of NOK 1.2 bn.

  • Norcod (NCOD.OL) traded up 9.12 % and now trades at NOK 21. Current market capitalisation for Norcod is NOK 1.6 bn.

About Photocure Asa

Photocure ASA is a specialty pharmaceutical company engaged in the research, development, production, distribution, marketing, and sale of pharmaceutical products and related technical medical equipment in Nordic countries and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer and is developing Visonac for the treatment of moderate to severe acne and Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. Photocure ASA sells its products to license partners, pharmaceutical wholesalers, and hospitals. The company was founded in 1997 and has its headquarters in Oslo, Norway. You can find more information about the company and its products on their website at www.photocure.com and they are listed on the Oslo Bors ASA.